Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VHL | P40337 | 13/20 | 0.45 |
| ▸ | ELOC | Q15369 | 3/20 | 0.42 |
| ▸ | ELOB | Q15370 | 3/20 | 0.42 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.37 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
| ▸ | SMARCA2 | P51531 | 2/20 | 0.36 |
| ▸ | SMARCA4 | P51532 | 2/20 | 0.36 |
| ▸ | EGFR | P00533 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25903959 | 0.89 | VHL (0.44) | VHLELOCELOBSOS1LRRK2 | |
| SCHEMBL25893485 | 0.89 | VHL (0.46) | VHLELOCELOBSOS1ACACB | |
| SCHEMBL25769171 | 0.85 | VHL (0.58) | VHLELOCELOBSOS1ACACB | |
| SCHEMBL23205254 | 0.84 | VHL (0.52) | VHLELOCELOBSOS1EGFR | |
| SCHEMBL25903022 | 0.83 | VHL (0.54) | VHLELOCELOBSOS1SMARCA2 | |
| SCHEMBL25898817 | 0.83 | VHL (0.51) | VHLELOCELOBSOS1 | |
| SCHEMBL25896727 | 0.83 | VHL (0.45) | VHLELOCELOBSOS1ACACB | |
| SCHEMBL25900160 | 0.82 | VHL (0.48) | VHLELOCELOBACACBSMARCA2 | |
| SCHEMBL25900704 | 0.81 | VHL (0.45) | VHLELOCELOBSOS1LRRK2 | |
| SCHEMBL25894289 | 0.81 | VHL (0.48) | VHLELOCELOBSOS1LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023141570-A2 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS | ARVINAS OPERATIONS, INC. (US) | 2023-07-27 | — | — | WO | disclosed |